Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.

Autor: Rofo F; Protein Drug Design, Faculty of Pharmacy, Uppsala University, 75124, Uppsala, Sweden., Buijs J; Department of Immunology, Genetics and Pathology, Uppsala University, 75185, Uppsala, Sweden.; Ridgeview Instruments, 75237, Uppsala, Sweden., Falk R; BioArctic AB, 11251, Stockholm, Sweden., Honek K; BioArctic AB, 11251, Stockholm, Sweden., Lannfelt L; BioArctic AB, 11251, Stockholm, Sweden.; Department of Public Health and Caring Sciences, Uppsala University, 75185, Uppsala, Sweden., Lilja AM; BioArctic AB, 11251, Stockholm, Sweden., Metzendorf NG; Protein Drug Design, Faculty of Pharmacy, Uppsala University, 75124, Uppsala, Sweden., Gustavsson T; Department of Public Health and Caring Sciences, Uppsala University, 75185, Uppsala, Sweden., Sehlin D; Department of Public Health and Caring Sciences, Uppsala University, 75185, Uppsala, Sweden., Söderberg L; BioArctic AB, 11251, Stockholm, Sweden., Hultqvist G; Protein Drug Design, Faculty of Pharmacy, Uppsala University, 75124, Uppsala, Sweden. greta.hultqvist@farmbio.uu.se.
Jazyk: angličtina
Zdroj: Translational neurodegeneration [Transl Neurodegener] 2021 Sep 28; Vol. 10 (1), pp. 38. Date of Electronic Publication: 2021 Sep 28.
DOI: 10.1186/s40035-021-00258-x
Abstrakt: Background: Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer's disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of efficacy or side-effects, two antibodies are currently in phase 3, and one has been approved by FDA. The soluble intermediate aggregated species of Aβ, termed oligomers and protofibrils, are believed to be key pathogenic forms, responsible for synaptic and neuronal degeneration in AD. Therefore, antibodies that can strongly and selectively bind to these soluble intermediate aggregates are of great diagnostic and therapeutic interest.
Methods: We designed and recombinantly produced a hexavalent antibody based on mAb158, an Aβ protofibril-selective antibody. The humanized version of mAb158, lecanemab (BAN2401), is currently in phase 3 clinical trials for the treatment of AD. The new designs involved recombinantly fusing single-chain fragment variables to the N-terminal ends of mAb158 antibody. Real-time interaction analysis with LigandTracer and surface plasmon resonance were used to evaluate the kinetic binding properties of the generated antibodies to Aβ protofibrils. Different ELISA setups were applied to demonstrate the binding strength of the hexavalent antibody to Aβ aggregates of different sizes. Finally, the ability of the antibodies to protect cells from Aβ-induced effects was evaluated by MTT assay.
Results: Using real-time interaction analysis with LigandTracer, the hexavalent design promoted a 40-times enhanced binding with avidity to protofibrils, and most of the added binding strength was attributed to the reduced rate of dissociation. Furthermore, ELISA experiments demonstrated that the hexavalent design also had strong binding to small oligomers, while retaining weak and intermediate binding to monomers and insoluble fibrils. The hexavalent antibody also reduced cell death induced by a mixture of soluble Aβ aggregates.
Conclusion: We provide a new antibody design with increased valency to promote binding avidity to an enhanced range of sizes of Aβ aggregates. This approach should be general and work for any aggregated protein or repetitive target.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje